| Literature DB >> 30420799 |
Roberta Ferrucci1,2,3, Simona Mrakic-Sposta1,4, Simona Gardini5, Fabiana Ruggiero1, Maurizio Vergari1, Francesca Mameli1, Andrea Arighi1,6, Marco Spallazzi7, Federica Barocco7, Giovanni Michelini5, Anna Margherita Pietroboni1,6, Laura Ghezzi1,6, Giorgio Giulio Fumagalli1,6,8, Giordano D'Urso9, Paolo Caffarra7,10, Elio Scarpini1,6, Alberto Priori2,3, Sara Marceglia1,11.
Abstract
Fronto-temporal dementia (FTD) is the clinical-diagnostic term that is now preferred to describe patients with a range of progressive dementia syndromes associated with focal atrophy of the frontal and anterior temporal cerebral regions. Currently available FTD medications have been used to control behavioral symptoms, even though they are ineffective in some patients, expensive and may induce adverse effects. Alternative therapeutic approaches are worth pursuing, such as non-invasive brain stimulation with transcranial direct current (tDCS). tDCS has been demonstrated to influence neuronal excitability and reported to enhance cognitive performance in dementia. The aim of this study was to investigate whether applying Anodal tDCS (2 mA intensity, 20 min) over the fronto-temporal cortex bilaterally in five consecutive daily sessions would improve cognitive performance and behavior symptoms in FTD patients, also considering the neuromodulatory effect of stimulation on cortical electrical activity measured through EEG. We recruited 13 patients with FTD and we tested the effect of Anodal and Sham (i.e., placebo) tDCS in two separate experimental sessions. In each session, at baseline (T0), after 5 consecutive days (T1), after 1 week (T2), and after 4 weeks (T3) from the end of the treatment, cognitive and behavioral functions were tested. EEG (21 electrodes, 10-20 international system) was recorded for 5 min with eyes closed at the same time points in nine patients. The present findings showed that Anodal tDCS applied bilaterally over the fronto-temporal cortex significantly improves (1) neuropsychiatric symptoms (as measured by the neuropsychiatric inventory, NPI) in FTD patients immediately after tDCS treatment, and (2) simple visual reaction times (sVRTs) up to 1 month after tDCS treatment. These cognitive improvements significantly correlate with the time course of the slow EEG oscillations (delta and theta bands) measured at the same time points. Even though further studies on larger samples are needed, these findings support the effectiveness of Anodal tDCS over the fronto-temporal regions in FTD on attentional processes that might be correlated to a normalized EEG low-frequency pattern.Entities:
Keywords: EEG; fronto-temporal dementia; neuromodulation; neuropsychiatric inventory; reaction time; transcranial direct current stimulation (tDCS)
Year: 2018 PMID: 30420799 PMCID: PMC6215856 DOI: 10.3389/fnbeh.2018.00235
Source DB: PubMed Journal: Front Behav Neurosci ISSN: 1662-5153 Impact factor: 3.558
Demographic and clinical features of the enrolled patients.
| 1 | 13 | 24 | BV | 138 | 38 | Anti-hypertensive; Antidepressive |
| 2 | 13 | 25 | PPA | 205 | 70 | Anti-hypertensive; Antipsicotic; Cholinesterase Inhibitor; Insuline; Antiplatelet; Statins |
| 3 | 13 | 21 | BV | 1,119 | 89 | Anti-hypertensive |
| 4 | 5 | 28 | BV | 32 | 17 | Antipsicotic; |
| 5 | 13 | 23 | BV | 586 | 71 | Antipsicotic |
| 6 | 18 | 22 | PPA | 1,005 | 95 | Anti-depressive |
| 7 | 18 | 27 | PPA | 580 | 61 | Anti-hypertensive; |
| 8 | 13 | 30 | BV | 363 | 84 | Anti-hypertensive; Anti-depressive |
| 9 | 8 | 20 | BV | 371 | 164 | Statins |
| 10 | 13 | 25 | BV | 313 | 35 | Anti-hypertensive; Anti-depressive |
| 11 | 8 | 28 | PPA | 211 | 81 | Antiplatelet; Antipsicotic |
| 12 | 5 | 30 | BV | 237 | 128 | Anti-hypertensive; Anti-depressive; Statins |
| 13 | 13 | 21 | PPA | 864 | 86 | Antipsicotic |
MMSE, mini mental state examination; FTD, fronto-temporal dementia; BV, behavioral variant of FTD; PPA, primary progressive aphasia; SD, standard deviation; anti-hypertensive: nifedipine, candesartancilexetil, amlodipine, indapamide hemihydrates, hydrochlorothiazide/irbesartan, nebivolol; anti-depressive: citalopram; antipsicotic: quetiapine, promazine, haloperidol; cholinesterase inhibitor: rivastigmine; antiplatelet: cardioaspirine; statins: atorvastatin, antidiabetic: metformin; anxiolytic: hydroxyzine hydrochloride.
Figure 1Transcranial Direct Current Stimulation (tDCS) experimental protocol. tDCS was applied bilaterally over the scalp on the Fronto-Temporal lobes for 5 consecutive days. Patients were assessed at baseline (T0), after 5 consecutive days of treatment (T1), after 1 week (T2), and after 4 weeks (T3) from the end of tDCS treatment.
Figure 2Findings on clinical variables (A). Effect of Anodal (black squares) and Sham (white squares) tDCS on the Neuropsychiatric Inventory (NPI). Squares represent the average NPI score on the 12 subjects analyzed, at T0, T1, T2, and T3. Error bars are standard deviations. ***p < 0.01 at the post-hoc Wilcoxon signed ranked test with Bonferroni correction (significant); (B). Effect of Anodal (black squares) and Sham (white squares) tDCS on the simple Visual Reaction Time (sVRT) test. Squares represent the average sVRT score on the 12 subjects analyzed, at T0, T1, T2, and T3. Error bars are standard deviations. **p < 0.01 at the post-hoc Wilcoxon signed ranked test with Bonferroni correction (significant) (C). Effect of Anodal (black squares) and Sham (white squares) tDCS on the Frontal Behavioral Inventory (FBI-A). Squares represent the average FBI-A score on the 12 subjects analyzed, at T0, T1, T2, and T3. Error bars are standard deviations (D). Scatter plot of the correlation between TAU protein (pg/mL) and MMSE score. The line represents the estimated linear regression. *p < 0.05.
qEEG power in the low- and high- frequency bands at all time points and in all regions of interest.
| LF | 14.86 ± 13.08 | 9.53 ± 10.90 | 10.36 ± 4.88 | 7.95 ± 5.95 | LF | 26.76 ± 32.74 | 20.54 ± 27.21 | 28.15 ± 30.87 | 14.35 ± 11.07 | ||
| HF | 5.42 ± 1.68 | 3.40 ± 1.62 | 3.87 ± 0.85 | 4.85 ± 1.59 | HF | 5.98 ± 2.81 | 4.80 ± 1.68 | 4.85 ± 1.84 | 5.14 ± 2.09 | ||
| LF | 30.41 ± 26.43 | 19.42 ± 22.31 | 18.13 ± 9.26 | 14.78 ± 9.55 | LF | 52.38 ± 71.09 | 41.99 ± 57.71 | 58.72 ± 66.36 | 27.13 ± 26.02 | ||
| HF | 9.48 ± 2.29 | 6.98 ± 3.70 | 6.42 ± 2.30 | 7.44 ± 2.61 | HF | 19.45 ± 18.28 | 12.65 ± 7.42 | 14.23 ± 8.76 | 15.77 ± 7.73 | ||
| LF | 27.12 ± 22.98 | 18.09 ± 17.41 | 15.74 ± 12.74 | 10.44 ± 10.45 | LF | 49.22 ± 69.20 | 44.15 ± 60.68 | 48.57 ± 60.68 | 19.39 ± 22.18 | ||
| HF | 9.69 ± 6.13 | 7.79 ± 4.25 | 6.00 ± 1.28 | 5.34 ± 4.48 | HF | 12.18 ± 8.52 | 10.37 ± 9.31 | 10.04 ± 10.25 | 9.62 ± 7.09 | ||
| LF | 48.46 ± 29.43 | 39.86 ± 30.02 | 46.13 ± 37.49 | 29.64 ± 34.11 | LF | 89.11 ± 107.82 | 70.74 ± 82.90 | 86.16 ± 105.10 | 40.18 ± 42.29 | ||
| HF | 30.56 ± 18.28 | 29.06 ± 24.48 | 27.99 ± 39.35 | 25.35 ± 45.79 | HF | 59.75 ± 90.60 | 32.34 ± 28.84 | 35.23 ± 33.71 | 32.05 ± 34.33 | ||
Figure 3Correlations between qEEG and clinical variables (A). Scatter plot of the correlation between the low-frequency (LB) band power calculated in the frontal area and the NPI scores. Black circles represent the values during the Anodal tDCS session, while the white circles represent the values during the Sham tDCS session. The scatter plot represents all the values at all time points (T0, T1, T2, and T3) (B). Scatter plot of the correlation between the low-frequency (LB) band power calculated in the frontal area and the sVRT scores. Black circles represent the values during the Anodal tDCS session, while the white circles represent the values during the Sham tDCS session. The scatter plot represents all the values at all time points (T0, T1, T2, and T3) (C). Scatter plot of the correlation between the low-frequency (LB) band power calculated in the temporo-parietal area and the sVRT scores. Black circles represent the values during the Anodal tDCS session, while the white circles represent the values during the Sham tDCS session. The scatter plot represents all the values at all time points (T0, T1, T2, and T3).